ATE437652T1 - Verwendung von hmgb1 zur aktivierung dendritischer zellen - Google Patents

Verwendung von hmgb1 zur aktivierung dendritischer zellen

Info

Publication number
ATE437652T1
ATE437652T1 AT02775057T AT02775057T ATE437652T1 AT E437652 T1 ATE437652 T1 AT E437652T1 AT 02775057 T AT02775057 T AT 02775057T AT 02775057 T AT02775057 T AT 02775057T AT E437652 T1 ATE437652 T1 AT E437652T1
Authority
AT
Austria
Prior art keywords
hmgb1
dendritic cells
activate dendritic
activate
apc
Prior art date
Application number
AT02775057T
Other languages
English (en)
Inventor
Marco Bianchi
Angelo Manfredi
Original Assignee
San Raffaele Centro Fond
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by San Raffaele Centro Fond filed Critical San Raffaele Centro Fond
Application granted granted Critical
Publication of ATE437652T1 publication Critical patent/ATE437652T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT02775057T 2001-09-25 2002-09-25 Verwendung von hmgb1 zur aktivierung dendritischer zellen ATE437652T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT2001MI001986A ITMI20011986A1 (it) 2001-09-25 2001-09-25 Metodo e composizione per l'attivazione di cellule presentanti l'antigene
PCT/IB2002/004080 WO2003026691A2 (en) 2001-09-25 2002-09-25 Use of hmgb1 for the activation of dendritic cells

Publications (1)

Publication Number Publication Date
ATE437652T1 true ATE437652T1 (de) 2009-08-15

Family

ID=11448420

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02775057T ATE437652T1 (de) 2001-09-25 2002-09-25 Verwendung von hmgb1 zur aktivierung dendritischer zellen

Country Status (9)

Country Link
US (1) US20040242481A1 (de)
EP (1) EP1432441B1 (de)
JP (1) JP2005508913A (de)
AT (1) ATE437652T1 (de)
AU (1) AU2002341266B2 (de)
CA (1) CA2461091A1 (de)
DE (1) DE60233147D1 (de)
IT (1) ITMI20011986A1 (de)
WO (1) WO2003026691A2 (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050112121A1 (en) * 1992-04-30 2005-05-26 Yale University Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids
GB0226251D0 (en) * 2002-11-11 2002-12-18 San Raffaele Centro Fond Acetylated protein
WO2006138429A2 (en) 2005-06-16 2006-12-28 The Feinstein Institute For Medical Research Antibodies against hmgb1 and fragments thereof
WO2007130725A2 (en) * 2006-02-06 2007-11-15 University Of Pittsburgh Of The Commonwealth System Of Higher Education Use of hmgb1 for protection against ischemia reperfusion injury
AU2007315073A1 (en) * 2006-10-30 2008-05-08 Genomix Co., Ltd. Pharmaceuticals that promote functional regeneration of damaged tissues
TW200900077A (en) * 2007-02-15 2009-01-01 Univ Kyushu Nat Univ Corp Therapeutic agent for interstitial pulmonary disease comprising anti-HMGB-1 antibody
US8470325B2 (en) 2007-02-15 2013-06-25 Kagoshima University Method of treating amykloidosis comprising administering an anti-HMGB-1 antibody
US20100173277A1 (en) * 2007-02-15 2010-07-08 Fukuoka University Agent for Suppressing Rejection in Organ Transplantation Comprising Anti-HMGB-1 Antibody
PL3097926T3 (pl) 2007-11-01 2020-04-30 The Board Of Trustees Of The University Of Arkansas Kompozycje i sposoby wzmacniania odpowiedzi odpornościowych na Eimeria
KR20110017371A (ko) 2008-04-30 2011-02-21 가부시키가이샤 제노믹스 생체내 기능적 세포의 고효율 채취법
WO2009133939A1 (ja) 2008-04-30 2009-11-05 株式会社ジェノミックス 末梢循環への骨髄由来多能性幹細胞動員薬
AU2009240885A1 (en) * 2008-04-30 2009-11-05 Genomix Co., Ltd. Pharmaceutical agent for promoting the functional regeneration of damaged tissue
KR20120135190A (ko) 2009-10-28 2012-12-12 고꾸리쯔 다이가꾸 호우징 오사까 다이가꾸 골수 간엽계 및/또는 다능성 줄기세포의 혈중 동원(動員)에 의한 조직 재생 촉진제
HUE037157T2 (hu) 2010-01-21 2018-08-28 Univ Arkansas Vakcinavektorok, és eljárások immunválaszok fokozására
WO2011123396A1 (en) 2010-03-29 2011-10-06 University Of Southern California Compositions and methods for the removal of biofilms
KR102008120B1 (ko) 2010-06-09 2019-08-07 더 보드 오브 트러스티스 오브 더 유니버시티 오브 아칸소 캄필로박터 감염을 감소시키기 위한 백신 및 방법
AU2011299025B2 (en) * 2010-09-09 2015-07-09 Nationwide Children's Hospital, Inc. Compositions and methods for the removal of biofilms
CN103687946B (zh) 2011-04-26 2017-05-03 吉诺米克斯股份有限公司 用于诱导组织再生的肽及其应用
US9244074B2 (en) 2011-06-07 2016-01-26 University Of Hawaii Biomarker of asbestos exposure and mesothelioma
WO2012170742A2 (en) * 2011-06-07 2012-12-13 University Of Hawaii Treatment and prevention of cancer with hmgb1 antagonists
CN104955470B (zh) 2012-10-25 2017-06-16 吉诺米克斯股份有限公司 利用了hmgb1片段的针对脊髄损伤的新型治疗方法
PL2913058T3 (pl) 2012-10-25 2018-04-30 Genomix Co., Ltd. Nowy sposób leczenia zawału mięśnia sercowego przy użyciu fragmentu HMGB1
EA030929B1 (ru) 2013-02-14 2018-10-31 Дзе Борд Оф Трастиз Оф Дзе Юниверсити Оф Арканзас КОМПОЗИЦИИ И СПОСОБЫ УСИЛЕНИЯ ИММУННЫХ ОТВЕТОВ НА Eimeria ИЛИ ОГРАНИЧЕНИЯ ИНФЕКЦИИ Eimeria
BR112015023024B1 (pt) 2013-03-15 2022-04-19 The Board Of Trustees Of The University Of Arkansas Vetor de vacina e composições farmacêuticas compreendendo o mesmo
US11274144B2 (en) 2013-06-13 2022-03-15 Research Institute At Nationwide Children's Hospital Compositions and methods for the removal of biofilms
US9745366B2 (en) 2013-09-23 2017-08-29 University Of Southern California Compositions and methods for the prevention of microbial infections
US11248040B2 (en) 2013-09-26 2022-02-15 Trellis Bioscience, Llc Binding moieties for biofilm remediation
US10233234B2 (en) 2014-01-13 2019-03-19 Trellis Bioscience, Llc Binding moieties for biofilm remediation
AU2016303688B2 (en) 2015-07-31 2023-06-15 Research Institute At Nationwide Children's Hospital Peptides and antibodies for the removal of biofilms
US10130658B2 (en) * 2015-12-18 2018-11-20 Provectus Pharmatech, Inc. Method of ex vivo enhancement of immune cell activity for cancer immunotherapy with a small molecule ablative compound
GB201600075D0 (en) 2016-01-03 2016-02-17 Glaxosmithkline Biolog Sa Immunogenci composition
TWI758288B (zh) 2016-05-03 2022-03-21 阿肯色州大學董事會 包含免疫刺激性及抗原性多肽的酵母菌疫苗載體以及其使用方法
WO2018047917A1 (ja) * 2016-09-09 2018-03-15 国立大学法人 東京大学 Ｈｍｇタンパク質と抗ｃｄ４抗体又は免疫チェックポイント制御剤との組み合わせによる相乗的抗腫瘍効果
BR112019014921A2 (pt) 2017-01-27 2020-03-31 StemRIM Inc. Agente terapêutico para miocardiopatia, infarto antigo do miocárdio e insuficiência cardíaca crônica
US11746136B2 (en) 2017-03-15 2023-09-05 Research Institute At Nationwide Children's Hospital Composition and methods for disruption of bacterial biofilms without accompanying inflammation
US12421498B2 (en) 2017-12-01 2025-09-23 StemRIM Inc. Ectodermal mesenchymal stem cells and method for producing same
JPWO2019107530A1 (ja) 2017-12-01 2020-11-26 株式会社ステムリム 炎症性腸疾患の治療薬
WO2019156137A1 (ja) 2018-02-08 2019-08-15 株式会社ステムリム 乾癬の治療薬
KR20210070331A (ko) 2018-10-05 2021-06-14 더 리서치 인스티튜트 앳 네이션와이드 칠드런스 하스피탈 생물막 제거를 위한 hmgb1 단백질 유도체
US12304933B2 (en) 2018-10-05 2025-05-20 StemRIM Inc. Disease treatment drug based on mesenchymal-stem-cell mobilization

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5214131A (en) * 1988-05-06 1993-05-25 Sumitomo Pharmaceuticals Company, Limited Polyethylene glycol derivatives, modified peptides and production thereof
US5091176A (en) * 1988-11-02 1992-02-25 W. R. Grace & Co.-Conn. Polymer-modified peptide drugs having enhanced biological and pharmacological activities
JPH04218000A (ja) * 1990-02-13 1992-08-07 Kirin Amgen Inc 修飾ポリペプチド
US5811512A (en) * 1991-08-22 1998-09-22 The Trustees Of The University Of Pennsylvania Non-peptide peptidomimetics and related cyclic hexapeptides
US5580853A (en) * 1994-03-22 1996-12-03 New England Deaconess Hospital Modified polypeptides with increased biological activity
US5891418A (en) * 1995-06-07 1999-04-06 Rhomed Incorporated Peptide-metal ion pharmaceutical constructs and applications
FR2739292B1 (fr) * 1995-09-28 1997-10-31 Rhone Poulenc Rorer Sa Composition pharmaceutique utile pour la transfection d'acides nucleiques et ses utilisations
IT1299583B1 (it) * 1998-05-19 2000-03-16 Vander Way Limited Uso di proteine hmg-i per la preparazione di medicamenti ad attivita' citotossica
US6100090A (en) * 1999-06-25 2000-08-08 Isis Pharmaceuticals Inc. Antisense inhibition of PI3K p85 expression
US6303321B1 (en) * 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis

Also Published As

Publication number Publication date
WO2003026691A3 (en) 2003-05-30
ITMI20011986A1 (it) 2003-03-25
CA2461091A1 (en) 2003-04-03
DE60233147D1 (de) 2009-09-10
WO2003026691A2 (en) 2003-04-03
US20040242481A1 (en) 2004-12-02
JP2005508913A (ja) 2005-04-07
EP1432441A2 (de) 2004-06-30
ITMI20011986A0 (it) 2001-09-25
AU2002341266B2 (en) 2007-11-15
EP1432441B1 (de) 2009-07-29

Similar Documents

Publication Publication Date Title
ATE437652T1 (de) Verwendung von hmgb1 zur aktivierung dendritischer zellen
DE59903410D1 (de) Hybridprotein zur hemmung der mastzelldegranulation und dessen verwendung
DE60324430D1 (de) Methode um rekombinante proteine in cho zellen zu exprimieren
BE2010C021I2 (de)
DE69826465D1 (de) Verfahren zur in vitro evolution von proteinfunktionen
WO2001064835A8 (en) Novel nucleic acids and polypeptides
DE69942459D1 (de) Isolierte nukleinsäuremoleküle die t-zellen induzierbare faktoren kodieren (tif), kodierte proteine und ihre anwendung
DE69930955D1 (de) Polypeptide mit lysophospholipaseaktivität und nukleinesäuren die sie kodieren
ATE384119T1 (de) Isoprenoidproduktion
DE602004025943D1 (de) Mikrosomvakzin
ATE368688T1 (de) Peptide, deren herstellung und verwendung zur bindung von immunglobulinen
ATE474926T1 (de) Verwendung von clya hemolysin fur ausscheidung von fusionprotein
ATE448312T1 (de) Leitsequenzen zur verwendung bei der produktion von proteinen
CY1109207T1 (el) Διαδικασια εχινοκανδινης
ATE446314T1 (de) Methode zur reinigung von fsh
DK1117798T3 (da) Fungal transskriptionel aktivator egnet ved fremgangsmåder til produktion af polypeptider
ATE306498T1 (de) Von zellen präsentierte peptide
ATE384787T1 (de) Tripeptidyl-aminopeptidase
DE60331224D1 (de) Subtilisin-carlsberg-proteine mit verminderter immunogenität
DK1344827T3 (da) Frostbeskyttende proteiner fra basidiomycetes
DK1145012T3 (da) Fremgangsmåder og kits til sekventering af polypeptider
DE60320302D1 (de) Verfahren zur identifikation von modulatoren des humanen orexin-2-rezeptors
DK1756273T3 (da) Signalpeptid til frembringelse af et polypeptid
DE60217651D1 (de) Zur modulation der krebszellenproliferation geeignetes polynukleotid
ATE393213T1 (de) Dendritische zelle mit alpha-glycosylceramid- derivat und antigen zur verwendung bei der unterdrückung von immunreaktionen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties